PLUS THERAPEUTICS, INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
CNSY$0.68+19.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity/(Deficit
(UNAUDITED) (In thousands, except share data)
| Convertible · Additional · Total | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| preferred stock · Common stock · Treasury Stock · paid-in · Accumulated · stockholders’ | |||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · (deficit)/equity | |||||||||||||||
| Balance at December 31, 2024 | 1,952 | $ | — | 246,190 | $ | — | (10,337) | $ | (500) | $ | 485,030 | $ | (493,479) | $ | (8,949) |
| Stock-based compensation | — | — | — | — | — | — | 148 | — | 148 | ||||||
| Exercise of pre-funded warrants | — | — | 261,429 | 1 | — | — | (1) | — | — | ||||||
| Exercise of Series B Warrants from May 2024 PIPE | — | — | 19,912 | — | — | — | 882 | — | 882 | ||||||
| Exchange of warrants for notes payable | — | — | — | — | — | — | (3,694) | — | (3,694) | ||||||
| Issuance of common stock, pre-funded warrants and warrants for debt repayment | — | — | 162,789 | — | — | — | 5,373 | — | 5,373 | ||||||
| Net loss | — | — | — | — | — | — | — | (17,401) | (17,401) | ||||||
| Balance at March 31, 2025 | 1,952 | $ | — | 690,320 | $ | 1 | (10,337) | $ | (500) | $ | 487,738 | $ | (510,880) | $ | (23,641) |
| Balance at December 31, 2025 | 1,952 | $ | — | 5,557,371 | $ | 6 | (10,337) | $ | (500) | $ | 520,355 | $ | (515,865) | $ | 3,996 |
| Stock-based compensation | — | — | — | — | — | — | 1,022 | — | 1,022 | ||||||
| Cancellation of common stock | — | — | (272,821) | — | — | — | — | — | — | ||||||
| Issuance of common stock upon vesting of RSUs | — | — | 8,867 | — | — | — | — | — | — | ||||||
| Issuance of common stock upon public offering, net of issuance costs | — | — | 1,578,947 | 1 | — | — | 13,888 | — | 13,889 | ||||||
| Net loss | — | — | — | — | — | — | — | (6,946) | (6,946) | ||||||
| Balance at March 31, 2026 | 1,952 | $ | — | 6,872,364 | $ | 7 | (10,337) | $ | (500) | $ | 535,265 | $ | (522,811) | $ | 11,961 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.